Lakefront Biotherapeutics

1.2K posts

Lakefront Biotherapeutics banner
Lakefront Biotherapeutics

Lakefront Biotherapeutics

@LakefrontBio

Galapagos is now Lakefront Biotherapeutics.

Europe Katılım Mayıs 2011
447 Takip Edilen3.4K Takipçiler
Lakefront Biotherapeutics
Lakefront Biotherapeutics@LakefrontBio·
Press Release | Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update Galapagos will host a conference call and webcast presentation May 7, 2026, at 14:00 CET / 8:00 am ET. Read more in our press release: glpg.com/press-releases…
English
0
0
0
263
Lakefront Biotherapeutics
Lakefront Biotherapeutics@LakefrontBio·
Press Release | Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases. Read more in our press release: bit.ly/4s33hyo
English
0
0
2
325
Lakefront Biotherapeutics
Lakefront Biotherapeutics@LakefrontBio·
Press release | Galapagos Appoints Tania Philipp as Chief Human Resources Officer. A seasoned life sciences executive, Ms. Philipp joins Galapagos with a strong track record in change management. Read more: glpg.com/press-releases…
English
0
1
1
247
Lakefront Biotherapeutics
Lakefront Biotherapeutics@LakefrontBio·
Press release | Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors. Dr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board. Read more: glpg.com/press-releases…
English
0
1
2
292
Lakefront Biotherapeutics
Lakefront Biotherapeutics@LakefrontBio·
📢 Galapagos to Host Conference Call to Discuss Full Year 2025 Financial Results and Provide Fourth Quarter Business Update on February 23, 2026. For details, visit our Webcasts section: glpg.com/webcasts-event…
English
0
1
1
243
Lakefront Biotherapeutics
Lakefront Biotherapeutics@LakefrontBio·
As 2025 comes to a close, we want to thank our colleagues, our partners, the scientific communities and the patients who participate in our clinical studies for the collaboration, dedication, and shared purpose that define our work. Happy holidays!
English
1
0
0
233
Lakefront Biotherapeutics
Lakefront Biotherapeutics@LakefrontBio·
Press Release | Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor in Dermatomyositis and Systemic Lupus Erythematosus. Read more: glpg.com/press-releases…
English
0
0
0
196
Lakefront Biotherapeutics
Lakefront Biotherapeutics@LakefrontBio·
We are pleased to announce the formation of Galapagos’ Cross-Disciplinary Strategic Advisory Board. Our new advisors — Dr. Scott Brun, Dr. Rob Lenz, Elaine Sorg, and Dr. Nancy Valente — bring deep experience across scientific innovation, development, and commercialization.
English
0
0
0
262
Lakefront Biotherapeutics
Lakefront Biotherapeutics@LakefrontBio·
Press Release ǀ Galapagos Welcomes Dr. Neil Johnston and Devang Bhuva to its Board of Directors. New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board. Read more: glpg.com/press-releases…
English
0
1
3
266
Lakefront Biotherapeutics
Lakefront Biotherapeutics@LakefrontBio·
📢 Galapagos to Host Conference Call to Discuss First Nine Months of 2025 Financial Results and Business Update on November 6, 2025. For details, visit our Webcasts section: glpg.com/webcasts-event…
English
0
0
0
218
Lakefront Biotherapeutics
Lakefront Biotherapeutics@LakefrontBio·
Press Release ǀ Galapagos to present new data on its TYK2 inhibitor at #ACR25. At clinically relevant exposures, the drug candidate showed selective inhibition of TYK2-mediated signaling, while sparing the IL-10 anti-inflammatory pathway. Read more: glpg.com/press-releases…
English
0
0
2
360
Lakefront Biotherapeutics
Lakefront Biotherapeutics@LakefrontBio·
We’re pleased to welcome Fred Blakeslee as EVP & General Counsel, effective October 16. Having most recently served as VP, Transactions, Legal at AbbVie, Fred brings extensive legal and transactional expertise to the Galapagos executive team. Read more: glpg.com/press-releases…
English
0
0
0
256